P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells
Open Access
- 27 August 2024
- journal article
- research article
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 21 (5) , 511-522
Abstract
Background/Aim: Interferon-induced trans-membrane protein 1 (IFITM1) is known to be involved in breast cancer progression. We aimed to investigate its role in estrogen receptor (ER)-positive breast cancer cells with wild-type p53 and tamoxifen-resistant breast cancer cells. Materials and Methods: The ER-positive breast cancer cell lines, MCF-7 with wild-type p53 and T47D with mutant p53, were used. We established an MCF-7-derived tamoxifen-resistant cell line (TamR) by long-term culture of MCF-7 cells with 4-hydroxytamoxifen. Results: IFITM1 inhibition in MCF-7 cells significantly decreased cell growth and migration. MCF-7 cells with suppression of IFITM1 using siRNA or ruxolitinib showed reduced cell viability after tamoxifen treatment compared with that in the control MCF-7 cells. Unexpectedly, mRNA and protein levels of IFITM1 were decreased in TamR cells compared with those in MCF-7 cells. TamR cells with suppression of IFITM1 using siRNA or ruxolitinib showed no change in cell viability after treatment with tamoxifen. P53 knockdown using siRNA reduced the mRNA levels of IRF9 and increased mRNA and protein levels of SOCS3 in MCF-7 cells, suggesting that loss or mutation of p53 can affect the induction of IFITM1 via the JAK/STAT signaling pathway in breast cancer. Furthermore, MCF-7 cells with p53 knockdown using siRNA showed no decrease in cell viability after tamoxifen treatment or IFITM1 inhibition, indicating that p53 status may be important for cell death after tamoxifen treatment or IFITM1 inhibition. Conclusion: IFITM1 inhibition may enhance the sensitivity to tamoxifen based on p53-dependent enhancement of IFN signaling in wild-type p53, ER-positive breast cancer cells.Keywords
This publication has 33 references indexed in Scilit:
- Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysisESMO Open, 2023
- The JAK/STAT signaling pathway: from bench to clinicSignal Transduction and Targeted Therapy, 2021
- Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategiesJournal of Molecular Medicine, 2021
- Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progressionCancer Letters, 2021
- The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathologyExperimental & Molecular Medicine, 2020
- Emerging roles of p53 and other tumour-suppressor genes in immune regulationNature Reviews Immunology, 2016
- Long story short: p53 mediates innate immunityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2016
- SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer modelOncogene, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell linesInternational Journal of Cancer, 2011